abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus


Choi MY1, Fitzpatrick RD2, Buhler K1, Mahler M3, Fritzler MJ4. Autoimmun Rev. 2020 Jan 9:102463. doi: 10.1016/j.autrev.2020.102463. [Epub ahead of print]

Author Information

1 Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB T2N4N1, Canada.

2 Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.

3 Inova Diagnostics, San Diego, CA, United States of America.

4 Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB T2N4N1, Canada. Electronic address: fritzler@ucalgary.ca.


The discovery of autoantibodies to ribosomal proteins (anti-RibP) dates back more than fifty years when antibodies to ribosomes were identified in systemic lupus erythematosus (SLE) sera. Over the years, anti-RibP autoantibodies have been the subject of extensive study and became known as a highly specific biomarker for the diagnosis of SLE and were associated with neuropsychiatric SLE (NPSLE), lupus nephritis (LN) and hepatitis (LH). As demonstrated by experiments on cultured human cells and of murine models, there is evidence to suggest that anti-RibP may have a pathogenic role in LN and NPSLE. Despite a wealth of evidence, in comparison to other SLE autoantibodies such as anti-Sm and anti-dsDNA, anti-RibP has not been included in classification criteria for SLE. A significant challenge is the variability of assays used to detect anti-RibP, including the antigens and diagnostic platforms employed. This may account for the marked variation in frequencies (10-47%) in SLE and its association with clinical and demographic features reported in SLE cohorts. We performed a systematic literature review and meta-analysis to help clarify its prevalence, various clinical and serological associations in SLE based on the different RIBP antigens and assay platforms used.